CSL Limited

The Business

CSL is a global biopharmaceutical company with three divisions. CSL Behring, the core franchise generating roughly 70% of earnings, collects human blood plasma and fractionates it into therapies for immune deficiencies and bleeding disorders. CSL Seqirus is the world's second-largest influenza vaccine maker. CSL Vifor, acquired in 2022 for US$11.7 billion, sells iron deficiency and nephrology treatments. Three companies (CSL, Takeda, Grifols) control approximately 75% of the global immunoglobulin market. CSL's 300-plus plasma collection centres and proprietary yield technology give it a structural cost advantage that competitors have not closed.

Recent Performance

CSL's share price has fallen roughly 60% from its 2024 highs above A$250, a decline unmatched in the company's listed history. The catalyst was a cascading series of negative events: US$6.5 billion in Vifor-related impairments, the departure of CEO Paul McKenzie, and two rounds of guidance downgrades that broke the sell-side's trust. FY25 revenue grew 5.1% to US$15.6 billion off a base that itself grew modestly, but the headline was overshadowed by the write-downs and leadership turmoil.

Outlook

FY26 marks a trough year, with revenue expected to decline 2.3% to US$15.2 billion as channel destocking in immunoglobulin and Chinese albumin policy changes work through. Recovery follows from FY27: we forecast 6.9% revenue growth driven by normalising Ig demand, which is currently observable at mid-to-high single digits in end markets. EBITDA margins should expand from 32.5% to 34% by FY28 as the US$500 million transformation program, already 60% delivered through permanent cost reductions, reaches full effect.

Key Risks

A new class of drugs called FcRn antibodies (led by Argenx's Vyvgart) could displace 20-30% of the immunoglobulin market over the next decade. If no permanent CEO is appointed within 12 months, strategy paralysis could weigh materially on the company's ability to execute. A structural deceleration in Ig demand below 4% growth would undermine the recovery thesis.

What to Watch

The thesis-defining event is the permanent CEO appointment, expected in the second half of calendar 2026, which will confirm whether the board can attract a top-tier external hire or settles for an internal caretaker.

• August 2026 FY26 results confirm earnings trough — validates that the worst is behind and transformation savings are tracking to plan.
• Q4 CY2026 H1 FY27 trading update — the first clean post-destocking quarter; a mid-single-digit Ig growth print would materially de-risk the recovery thesis.
• 1-3 years Seqirus demerger decision — separating the flu vaccine business could unlock value currently obscured by the conglomerate structure.

Latest Developments

CSL reported H1 FY26 results in February 2026, confirming FY26 NPATA guidance of approximately US$3.1 billion. The company disclosed additional Vifor-related impairments, bringing total write-downs to US$6.5 billion. An interim CEO (Joy Naylor) was appointed following Paul McKenzie's departure, and a global search for a permanent replacement is underway.

Company Description

CSL operates three divisions, all reporting in US dollars. CSL Behring (US$11.2 billion, 72% of FY25 revenue) manufactures plasma-derived and recombinant therapies, with immunoglobulin products (Privigen, Hizentra) treating primary immunodeficiency (PID) and secondary immunodeficiency (SID) forming the largest product family. Behring also produces albumin, coagulation factors for haemophilia, and specialty products. CSL Seqirus (US$2.2 billion, 14%) is the world's number-two influenza vaccine maker, operating cell-based manufacturing that differentiates it from traditional egg-based production. CSL Vifor (US$2.2 billion, 14%) sells intravenous iron treatments (Ferinject/Injectafer) and nephrology therapies. All revenue is earned offshore; CSL is an ASX-listed company whose earnings are entirely denominated in US dollars and euros.

Where the Growth Is

Immunoglobulin therapy within CSL Behring is the single most important growth driver, contributing roughly 70% of group earnings. End-market demand for Ig is growing at 6-8% annually, driven by expanding diagnosis rates for PID and SID, and ageing demographics that increase autoimmune prevalence. This is structural, not cyclical: patients with primary immune deficiency require lifelong infusions with no alternative therapy. CSL's proprietary Rika and iNomi yield technology extracts approximately 10% more immunoglobulin per litre of plasma than competitors, translating into an estimated 200 basis point cost advantage.

Competitive Position

CSL's competitive advantages are deeply entrenched and unlikely to erode within a decade. The plasma supply chain is the moat. CSL operates over 300 collection centres globally, feeds them into an integrated fractionation network, and converts raw plasma into therapies through a 9-to-12 month production cycle. This vertical integration means a new competitor would need to simultaneously build collection infrastructure, secure regulatory approvals across dozens of countries, and fund years of working capital before generating a dollar of revenue. No company has successfully done this at scale in 30 years.

Three firms (CSL, Takeda, Grifols) control approximately 75% of the global Ig market. This oligopoly is self-reinforcing: the limited supply of human plasma constrains industry capacity, while biological manufacturing complexity creates regulatory barriers. Grifols is financially distressed at six times leverage, making it a less aggressive competitor. Argenx represents the one genuine structural threat: its FcRn antibody Vyvgart could displace Ig in autoimmune indications (roughly 25% of the Ig market) over 5-10 years, though it has no application in PID or SID, which form the biological demand floor.

Management & Capital Discipline

Management credibility is the weakest element of the CSL investment case. The US$11.7 billion acquisition of Vifor Pharma in 2022, completed near the top of the biotech valuation cycle, has resulted in US$6.5 billion of impairments, destroying roughly 13% of shareholder equity. Two consecutive guidance downgrades broke the sell-side's trust: management's growth guidance has achieved only 71% of its targets over recent years, though margin guidance has proven reliable at 97% delivery.

The honest observation is that management attributes 70% of its problems to external factors (destocking, China policy) when the Vifor overpayment and forecasting failures are clearly self-inflicted. The interim CEO, Joy Naylor, has been unusually candid about past mistakes, which is credibility-positive for risk assessment but does not resolve the strategic vacuum. Capital allocation outside Vifor has been solid: consistent free cash flow generation, a progressive dividend, and a recently initiated buyback program at attractive prices.

Financial Position

CSL's balance sheet is adequate but not a source of strength. Net debt sits at approximately US$10 billion, or 1.8 times EBITDA, with interest coverage of 12.6 times. The company holds investment-grade credit ratings. Liquidity of US$3.4 billion provides comfortable headroom. The balance sheet could absorb a 35% revenue decline before triggering financial stress. Post-impairment, the remaining asset base is higher quality (Behring core), though US$16 billion in intangible assets still dominates the balance sheet. Working capital intensity is elevated at 38% of sales due to the 9-12 month plasma production cycle, but this is structural to the industry rather than a sign of inefficiency.